Pages that link to "Q33763834"
Jump to navigation
Jump to search
The following pages link to Infectious complications in chronic lymphocytic leukaemia (Q33763834):
Displaying 14 items.
- A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia (Q26766388) (← links)
- Infectious morbidity in critically ill patients with cancer (Q34348047) (← links)
- Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL. (Q34785892) (← links)
- Immunologic monitoring in chronic lymphocytic leukemia (Q35190701) (← links)
- Reconstitution of innate immunity in B-chronic lymphocytic leukemia: time to reconsider the possibilities (Q35545072) (← links)
- Underlying disorders and their impact on the host response to infection (Q36291747) (← links)
- Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. (Q37098627) (← links)
- Autoimmune phenomena in untreated and treated marginal zone lymphoma (Q37890410) (← links)
- Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). (Q43430617) (← links)
- Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population (Q43947313) (← links)
- Segmental coecal cytomegalovirus colitis during fludarabine, cytarabine and mitoxantrone induction chemotherapy for myelodysplastic syndrome (Q44194399) (← links)
- The effect of immunoglobulinVH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia (Q59413319) (← links)
- Élaboration et mise en place par ActionCancer Manitoba d’un programme d’administration d’immunoglobuline par voie sous-cutanée (Q92428540) (← links)
- The development and implementation of a subcutaneous immunoglobulin (SCIG) program at CancerCare Manitoba (Q92428594) (← links)